Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents

NCT00894634 | Completed Phase 1

• 1 other identifier: BF-08-06
• Study Type: interventional
• Target: 37
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to \<12 yrs and adolescents aged 12 to \<18 yrs.

Conditions

Allergic Reactions

Outcome Measures

Primary Outcomes (1)

• Log transformed values of AUCL and Cmax

  72 hours

Study Arms (1)

Brompheniramine maleate

EXPERIMENTAL

Brompheniramine maleate oral solution 1 mg/5 mL, single dose

Drug: Brompheniramine maleate

Interventions

Brompheniramine maleate DRUG

Brompheniramine maleate

Eligibility Criteria

• Age: 2 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Males or females between 2 to less than 18 yrs of age with a minimum weight of 24 pounds and within the 5th and 95th percentiles in height and weight, and BMI based on age and gender
• Symptomatic or asymptomatic children/adolescents as follows:
• A prior diagnosis of allergic rhinitis and either symptomatic or asymptomatic at the time of entry in the study; or \* Symptoms of an acute URI; or
• No symptoms of an acute URI, but at risk for developing an acute URI as evidenced by the following frequency, crowding, and exposure criteria:
• Frequency: a history of frequent URIs defined as greater than 6 infections/yr for children aged 2 to less than 6 yrs and as greater than 4 infections per year for adolescents aged 6 to less than 18 yrs;
• Crowding: living in a home with greater than 4 persons, or sleeping in the same bedroom with greater than 3 persons;
• Exposure: the presence of another family member in the household who is ill with a URI, or a child in the family that is attending preschool, or attending school with greater than 6 children in the class;
• Except for allergic rhinitis or a URI, children/adolescents are in normal physical health (i.e., no clinically significant systemic disease) as judged by the Investigator upon physical examination of the subject;
• Subjects do not require concomitant medication except for low-dose inhaled glucocorticoids for allergic rhinitis or mild concomitant asthma, if dose is stabilized before entry in the study (i.e., dose is not changed for one month prior to or during the study), and inhaled short-acting beta-2 adrenergic agonists for concomitant asthma, as needed;
• Post menarchal females must be using a reliable method of contraception (i.e., oral, transdermal, injectable or implanted contraceptives, IUD, cervical cap, diaphragm, condom, abstinence, or surgical sterility).

You may not qualify if:

• The child/adolescent weighs less than 24 pounds or is below the 5th or above the 95th percentiles in physical growth characteristics (i.e., height and weight), and BMI based on age and gender;
• Inability to swallow the medication;
• Eaten within 2 hours prior to dosing;
• A known hypersensitivity to BROM, any other antihistamine, or EMLA cream;
• Systolic and/or diastolic blood pressure at or above the 95th percentile based on gender, and age and height percentiles. (Note: If a subject with no history of hypertension has a blood pressure reading at or above the 95th percentile, the subject will be allowed to rest for 15 minutes and the blood pressure measurement repeated. Up to 3 consecutive measurements at approximately 5 min intervals will be allowed. Subjects who continue to have systolic and/or diastolic blood pressure readings at or above the 95th percentile will be excluded from the study);
• History of melena or any hepatic, renal, endocrine (e.g., diabetes, thyroid disorder), cardiac, neurological, psychiatric, gastrointestinal, hematological or metabolic disorder deemed to be clinically significant by the Investigator;
• Any serious medical condition or medical history felt by the Investigator to place them at increased risk;
• The child is diagnosed with anemia or has a red blood cell count or hemoglobin level outside of normal range as evidenced by baseline hematology assessment;
• Failure to comply with appropriate washout periods for any H-1 receptor antagonist treatment before and during the study, i.e., no use within 7 days of entering the study or at any time during the study, and no use of astemizole within the preceding 3 calendar months;
• A history of drug, alcohol, or tobacco abuse (older children and adolescents), a history of Hepatitis B, a previous positive test for Hepatitis B surface antigen, or a previous positive Hepatitis C antibody;
• A history of HIV infection or previous demonstration of HIV antibodies;
• Female subjects who have experienced menarche and have a positive urine pregnancy test;
• Parent/guardian/subject judged by the Investigator to be unable or unwilling to comply with the requirements of the protocol;
• Have taken an investigational drug within 30 days prior to entering the study or have already participated in the trial;
• Relative of the Sponsor, Investigator, or any personnel of the study site who are directly involved with the study.

Sponsors & Collaborators

• Wyeth is now a wholly owned subsidiary of Pfizer: lead

Related Publications (1)

• Pathirana S, Jayawardena S, Meeves S, Thompson GA. Brompheniramine and Chlorpheniramine Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 Years. J Clin Pharmacol. 2018 Apr;58(4):494-503. doi: 10.1002/jcph.1037. Epub 2017 Nov 14.

  PMID: 29136286 DERIVED

MeSH Terms

Conditions

Hypersensitivity

Interventions

Brompheniramine

Condition Hierarchy (Ancestors)

Immune System Diseases

Intervention Hierarchy (Ancestors)

Pheniramine; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Medical Monitor

  Wyeth is now a wholly owned subsidiary of Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 5, 2009
• First Posted: May 7, 2009
• Study Start: March 21, 2009
• Primary Completion: April 26, 2009
• Study Completion: April 26, 2009
• Last Updated: October 23, 2020

Record last verified: 2020-10